Étiquette : Canada

National Retail Sales of Alcohol and Cannabis During the COVID-19 Pandemic in Canada, James MacKillop et al., 2021

National Retail Sales of Alcohol and Cannabis During the COVID-19 Pandemic in Canada James MacKillop, PhD; Alysha Cooper, MSc; Jean Costello, PhD JAMA Network Open, 2021, 4, (11), e2133076, 1-4. Doi : 10.1001/jamanetworkopen.2021.33076   Introduction There is concern that the societal consequences of the COVID-19 pandemic will be associated with increased substance use.1 Data to date have primarily been self-reported changes, but objective sales data may inform this question. Here, we examined national retail sales of alcohol and cannabis prior to and during the pandemic in Canada. Methods : Where applicable, the report for this economic evaluation is consistent with the Consolidated Health Economic Evaluation Reporting Standards [...]

Lire la suite

Cannabinoid Hyperemesis Syndrome : A Case Report and Discussion Regarding Patients with Concurrent Disorders, Stephen Lee-Cheong et al., 2020,

Cannabinoid Hyperemesis Syndrome : A Case Report and Discussion Regarding Patients with Concurrent Disorders Stephen Lee-Cheong, Amrita Grewal, Lukas Hestvik, Reza Rafizadeh, and Christian Schütz The Canadian Journal of Hospital Pharmacy, 2020, 73, (4), 290-293   INTRODUCTION In October 2018, Canada legalized the nonmedical use of cannabis. Usage has traditionally been high in Canada, and after legalization, self-reported use increased from 14% to 18%.1 Given this increased usage, it is important to understand the adverse effects of cannabis. Here, we focus on a less well-recognized consequence, cannabinoid hyperemesis syndrome (CHS), first described in 2004.2 It may be seen more often in jurisdictions where cannabis is legalized; [...]

Lire la suite

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence, Mélissa Prud’homme et al., 2015

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence Mélissa Prud’homme, Romulus Cata and Didier Jutras-Aswad Substance Abuse : Research and Treatment,  2015, 9, 33-38. doi : 10.4137/SART.S25081.   Abstract : Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of cannabis, is thought to modulate various neuronal circuits involved in drug addiction. The goal of this systematic review is to summarize the available preclinical and clinical data on the impact of CBD on addictive behaviors. MEDLINE and PubMed were searched [...]

Lire la suite

In Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues, Bo Wang et al., 2020

In Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues Bo Wang, Anna Kovalchuk, Dongping Li, Yaroslav Ilnytskyy, Igor Kovalchuk and Olga Kovalchuk Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 April 2020 doi : 10.20944/preprints202004.0315.v1   Abstract : With the rapidly growing pandemic of COVID-19 caused by the new and challenging to treat zoonotic SARS-CoV2 coronavirus, there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted [...]

Lire la suite

COVID-19, usage d’alcool et de cannabis, Canadian Center on Substance Use and Addiction, 2020

COVID-19, usage d’alcool et de cannabis Canadian Center on Substance Use and Addiction www.ccsa.ca • www.ccdus.ca Le présent document d’information vient compléter l’infographie COVID-19, usage d’alcool et de cannabis et décrit certains des liens factuels entre la COVID-19 et l’usage d’alcool et de cannabis. Le document s’adresse à un large public, notamment les professionnels de la santé, les décideurs et les chercheurs. Les risques associés à l’usage d’alcool et de cannabis sont plus importants pendant la pandémie de COVID-19. Face à cette menace constante, les Canadiens pourraient vivre des émotions et des situations qui influeront sur leur usage d’alcool et de cannabis, et tout [...]

Lire la suite

Canada : La consommation de cannabis des 15-17 ans a baissé de 47% depuis la légalisation, Newsweed, 20 février 2020, Aurélien BERNARD

Canada : La consommation de cannabis des 15-17 ans a baissé de 47% depuis la légalisation Newsweed, 20 février 2020 Par Aurélien BERNARD   Depuis la légalisation du cannabis au Canada en octobre 2018, Statistique Canada, l’organe statistique national, conduit tous les 3 mois une enquête pour récolter des données sur la consommation de cannabis des Canadiens. Malgré les limites inhérentes au déclaratif, ces données permettent d’entrevoir les effets de la légalisation sur les Canadiens. Consommation de cannabis selon l’âge Ainsi, après un an de légalisation, plus de 5,1 millions de Canadiens de 15 ans ou plus ont déclaré avoir consommé du cannabis en 2019 au cours [...]

Lire la suite

Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada, Elena ARGENTO et al., 2019

Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada Elena ARGENTO, Rielle CAPLER, Gerald THOMAS, Philippe LUCAS & Kenneth W. TUPPER Drug and Alcohol Review, 2019 Doi : 10.1111/dar.12985   Abstract Introduction and Aims. A previous observational study of ayahuasca-assisted therapy demonstrated statistically significant reductions in self-reported problematic cocaine use among members of an Indigenous community in Canada. This paper aims to qualitatively explore the impact of ayahuasca assisted therapy on addiction and other substance use-related outcomes and elucidate the lived experiences of participants. Design and Methods. Qualitative interviews were conducted with 11 adult Indigenous participants of the ayahuasca-assisted [...]

Lire la suite

Medical use of cannabis products. Lessons to be learned from Israel and Canada, Jacob Ablin et al., 2016

Medical use of cannabis products. Lessons to be learned from Israel and Canada J. Ablin, P.A. Ste-Marie, M. Schäfer, W. Häuser, M.-A. Fitzcharles Der Schmerz, 2016, 1-10 DOI 10.1007/s00482-015-0083-4 © Deutsche Schmerzgesellschaft e.V. Published by Springer-Verlag Berlin Heidelberg - all rights reserved 2015   Abstract Introduction : The German government intends to reduce the barriers for the medical use of cannabis products. A discussion on the indications and contraindications of the medical use of cannabis and on the changes of the regulatory framework has already begun in Germany. It is useful to draw from the experiences of other countries with a more liberal medical use of cannabis. Methods [...]

Lire la suite

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, Richard J. Huntsman et al., 2019

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in  Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716   Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]

Lire la suite

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite